AI Stock Analysis - Tenaya Therapeutics (TNYA)
Analysis generated December 22, 2025.
Tenaya Therapeutics is a biopharmaceutical company dedicated to developing treatments for heart diseases through gene therapy, cellular regeneration, and precision medicine. The company's focus is on leveraging modern biomedical advances to address unmet medical needs in cardiovascular health.
Stock Alerts - Tenaya Therapeutics (TNYA)
 |
Tenaya Therapeutics | March 10 Price is down by -6% in the last 24h. |
|
Tenaya Therapeutics | March 9 Price is up by 9.2% in the last 24h. |
|
Tenaya Therapeutics | March 6 Price is down by -6% in the last 24h. |
|
Tenaya Therapeutics | March 5 Price is up by 8.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Tenaya Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 6 | Sign up | Sign up | Sign up |
| Facebook Followers | 3,846 | Sign up | Sign up | Sign up |
| Instagram Followers | 235 | Sign up | Sign up | Sign up |
| Reddit Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 367 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,128 | Sign up | Sign up | Sign up |
| X Followers | 606 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 179 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 76 | Sign up | Sign up | Sign up |
| Linkedin Employees | 106 | Sign up | Sign up | Sign up |
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
| Price | $0.90 |
| Target Price | Sign up |
| Volume | 13,826,556 |
| Market Cap | $192M |
| Year Range | $0.55 - $2.1 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyMarch 9 - GlobeNewswire |
|
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026March 2 - GlobeNewswire |
|
Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap BiotechJanuary 12 - Yahoo Entertainment |
|
 |
Tenaya Therapeutics price target lowered by $3 at Morgan Stanley, here's whyJanuary 8 - Thefly.com |
 |
12 Health Care Stocks Moving In Thursday's Intraday SessionMarch 4 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 1.9M | -1.9M | -20M | -18M | -0.120 |
| Q2 '25 | 0 | 2.1M | -2.1M | -23M | -21M | -0.140 |
| Q1 '25 | 0 | 0 | 0 | -27M | -25M | -0.240 |
| Q4 '24 | 0 | 0 | 0 | -24M | -23M | -0.280 |
| Q3 '24 | 0 | 0 | 0 | -26M | -25M | -0.300 |
Insider Transactions View All
| Svennilson Peter filed to sell 1,649,281 shares at $0.6. February 26 '26 |
| Svennilson Peter filed to sell 1,862,545 shares at $0.6. February 26 '26 |
| Svennilson Peter filed to sell 1,958,509 shares at $0.6. February 24 '26 |
Similar companies
Read more about Tenaya Therapeutics (TNYA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Tenaya Therapeutics
The Market Cap of Tenaya Therapeutics is $192M.
Currently, the price of one share of Tenaya Therapeutics stock is $0.90.
The TNYA stock price chart above provides a comprehensive visual representation of Tenaya Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tenaya Therapeutics shares. Our platform offers an up-to-date TNYA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Tenaya Therapeutics (TNYA) does not offer dividends to its shareholders. Investors interested in Tenaya Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Tenaya Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
